Go or no go? Vaccines and neurology up for discussion
FDA panels loom for GSK and Biogen, with approval decisions due for Acadia and Biomarin.
Go or no go? Lecanemab’s destiny approaches
2023 begins with FDA decisions for Eisai’s Alzheimer’s project and Pfizer’s zavegepant, with an adcom for Cidara’s rezafungin.
Go or no go? Novartis eyes a big new growth driver
The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.
Japanese biopharma rules mid-cap returns
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Small and mid-cap share price gains make up for majors
Deals were a major driver of mid-cap share movement in the first quarter, but pipeline progress and misfires played their parts too.